Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises a consortium of Swedish and foreign banks in connection with the financing of the New Karolinska Hospital in Solna
Mandate

Vinge advises a consortium of Swedish and foreign banks in connection with the financing of the New Karolinska Hospital in Solna

July 05, 2010

Vinge and Clifford Chance have advised a consortium of Swedish and foreign banks in connection with the financing of the New Karolinska Hospital in Solna which will be built, run and maintained by Skanska and Innisfree on behalf of Stockholm County Council. The project is Skanska’s largest project to date with a total project value of approximately SEK 14.5 billion. This is also the second Swedish so-called PPP (Public Private Partnership) after the Alranda railway and, when completed in 2015, the new Karolinska Hopistal will be the world’s largest PPP hospital.

Vinge’s team consisted of partner Maria-Pia Midenbäck Hope and, among others, associates Dan Hanqvist, Maria Schultzberg, Peter Forsberg, Christina Rosén, Sofia Berg and Albert Wållgren.

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

 SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026